Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD
about
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatmentMedication-Induced Tardive Dyskinesia: A Review and Update.The DRD2 gene in psychiatric and neurological disorders and its phenotypes.Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes.Genetic polymorphisms in the expression and treatment of neuropsychiatric disorders.Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease.Clinical aspects and management of levodopa-induced dyskinesia.Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.Levodopa-induced dyskinesias and their management.Pharmacogenetics of Parkinson's disease - through mechanisms of drug actions.New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges.Parkinson's disease pharmacogenomics: new findings and perspectives.Cerebellum in levodopa-induced dyskinesias: the unusual suspect in the motor network.Pharmacogenetic considerations in the treatment of Parkinson's disease.A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.How close are we to individualized medicine for Parkinson's disease?Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's diseaseFast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent regionally selective, bimodal effects on striatal dopamine kinetics in vivo.The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.Brief communication: Allelic and haplotypic structure at the DRD2 locus among five North Indian caste populations.Age and severity of nigrostriatal damage at onset of Parkinson's disease.Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.Misgenotyping of dopamine receptor D1 gene -48A/G polymorphism.Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease.Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson's Disease.Gender effect on time to levodopa-induced dyskinesias.Motor Complications of Dopaminergic Medications in Parkinson's Disease.
P2860
Q24647141-0B2655BC-AD25-41AA-ABA2-2031A7EFDF91Q33802645-8AC75307-F73D-4B22-A119-6F4D3AA5F703Q34188497-2E0DF54F-F30E-4F2B-9B75-0112862D21ADQ34410406-26B4893D-4839-47FE-B3A6-D97A067A33C8Q35032700-49138674-CF7F-40AA-A7ED-38D5DDDC8562Q35294809-8CFC18A7-9BD4-4C19-AE24-AF8175C8390CQ35821201-8248D989-23DB-4253-AFCA-57E6C6213355Q36022700-50293090-62CA-4912-A0BD-E378DA764B3DQ36730631-0CEAFC09-2767-4ABD-A353-F77F8C71F78DQ37280804-915B3F88-D54C-4758-BE64-19AEE2F79EEDQ37583417-657ECD8E-6EFE-4721-870B-53FF950F6A26Q37853032-5775E1B9-C314-43E6-8DC1-5A52103109C1Q38241678-6F81CA87-3EAA-452E-A898-72AF7F2E8276Q38245731-A97A682D-3145-4ED7-BE8D-8828B3988F50Q38364825-79B3412E-A8E0-4040-B47B-6EF84B73BE54Q38662579-CFEA32A3-D1EA-45EA-8BA6-9464DE6FA4ACQ38814888-5CA9A2AF-7D60-4C1F-8ADA-6AB8540058F6Q38865983-30E2B9FB-8826-457B-90AF-B809C518C3CEQ40860918-5FA569B6-AB86-46FA-84DD-F19F68136D5EQ41711967-A843E81D-A9AC-4045-B547-04ACF4DC43E4Q42754446-9454BFA9-2F84-4CA5-B43A-3FF79D95B680Q42792207-466FFB59-DB0D-424D-964A-82E74487266BQ42859427-1F3FA3DB-265C-4186-979E-3E97F6CFA120Q43187354-84AAF6DB-0A16-46B8-A0B3-A923D734346FQ44231685-B8483D8B-68D0-4F42-896B-471C384012D6Q45007058-32FC8084-E53A-48E2-A9AF-07A1226D579CQ46492024-918E23A3-DFF5-4434-A6B0-154FF32EFC6AQ46910776-F4950936-C9DF-4FF7-AD56-3C7DC06E2F42Q47389217-D7817637-31BD-437C-AC43-309624393671Q47648607-7306A003-47BB-4C5A-819E-356E8E470908Q48880365-76FFD774-9FE9-435A-B798-C0A354455692Q50634271-9097F706-819C-49DE-827B-2A5C2C2255DEQ51469422-4356DB87-14A3-476D-8F5C-3FC03B7BDF23Q55279095-7E0DC09B-FD7D-4791-BC62-8871CA42601A
P2860
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD
@ast
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD
@en
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD
@nl
type
label
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD
@ast
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD
@en
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD
@nl
prefLabel
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD
@ast
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD
@en
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD
@nl
P2093
P50
P921
P356
P1433
P1476
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD
@en
P2093
A A Pasqua
A Quattrone
P Spadafora
R Cittadella
R L Oliveri
R Montesanti
V Andreoli
P304
P356
10.1212/WNL.53.7.1425
P407
P577
1999-10-01T00:00:00Z